Biosimilars are highly similar to the reference product in terms of safety, purity and potency, but may have minor differences in clinically inactive components. Any differences are carefully ...

Topical antifungals, although often effective, are being discouraged in the early treatment of seborrheic dermatitis now that ...

Formycon and Fresenius Kabi Canada receive Health Canada’s approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara® Otulfi ® approved by Health Canada for both subcutaneous and intravenous ...

Fresenius, through its operating company Fresenius Kabi, is broadening its growing biopharma portfolio through a new licensing agreement with South Korea’s SamChunDang Pharm. Under the agreement, ...

Fresenius is a strong buy with a 60% Return on Revenue potential in the next 3 years, driven by earnings growth and strategic ...

Approved by Health Canada for Both Subcutaneous and Intravenous Formulations to Treat Serious Inflammatory Diseases Health Canada Joins the FDA and the European Commission in Granting Regulatory ...

Capital Infra Trust IPO: Rs 703 Crore Mobilized from Anchor Investors Capital Infra Trust, an InvIT sponsored by Gawar Construction, has raised Rs 703 crore from anchor investors ahead of its IPO ...

In one of the biggest deals worldwide for a biosimilar brand, Ahmedabad-based Intas agreed to buy Udenyca-the brand name for ...

Amicus™ high collection efficiency yields multiple products per donor for the lowest-cost platelet production. It is designed to adapt to the requirements of different collection settings. Let ...

Alyx is designed to help optimize your bottom line with reduced labor and error related costs and the ability to increase collection of high value components.

Fresenius Medical Care AG & Co KGaA is a Germany-based holding and kidney dialysis company, operating in the fields of dialysis products and dialysis services. Its dialysis business is vertically ...